Head and Neck Imaging
Effect Comparison between Tegafur Gimeracil Otera Combined with Apatinib and Single-drug Tegafur Gimeracil Otera in Treating Advanced Gastric Cancer
Author：ZHANG Xi-ai
affiliation：Department of Oncology, The Third Affiliated Hospital of Xinxiang Medical College, Xinxiang 453000, Henan Province, China
PDFAbstract
Objective To investigate the clinic effect between Tegafur Gimeracil Otera combined with apatinib and single-drug Tegafur Gimeracil Otera in treating advanced gastric cancer. Methods 60 cases with advanced gastric cancer in our hospital from June 2016 to June 2017 were selected and divided into the observation group and the control group according to number table method, 30 cases in each group. The observation group was given Tegafur Gimeracil Otera combined with apatinib and the control group was given single-drug Tegafur Gimeracil Otera, clinic effect and adverse reactions of the two groups after treatment were observed. Results After treatment, total efficiency of the observation group (93.33%) was significantly higher than that of the control group (63.33%), adverse reaction rate of the control group (33.33%) was significantly higher than that of the observation group (6.67%), the difference was statistic significant (P<0.05). Conclusion Tegafur Gimeracil Otera combined with apatinib in treating advanced gastric cancer can improve clinic effect, toxic and side effect are tolerable, it is worthy of promotion.
【Keyword】Tegafur Gimeracil Otera; Apatinib; Advanced Gastric Cancer; Clinic Effect
【Chart number】R735.2
【Document Identification Number】A
【DOI】10.3969/j.issn.1009-3257.2018.02.015
Journal of Rare Diseases
th25Volume， th 2 Issue
2019Year11Month
Related articles
Editor email：（1）中国CT和MRI杂志：ctmri@vip.163.com；（2）罕少疾病杂志：hs1999@vip.163.com
Contact number：0755-83695203
Our address：
English
简体中文
logged in
Wechat
TouTiao